EGFR and non-small cell lung carcinoma: In the advanced NSCLC patients with EGFR mutation and BM who received chemotherapy as the first-line setting, the median PFS and OS were similar in both groups (median PFS: 6.4 vs. 7.2 months, HR = 1.09, 95% CI 0.71–1.72, P = 0.674; median OS: 15.5 vs 14.1 months, HR = 0.84, 95% CI 0.56–1.25, P = 0.384) (Fig. 3B,E).